First JCI & NABH Accredited Multispeciality Health Care Hospital in Gurgaon

Book Appointments On Application

Dr. Hari Goyal

Dr. Hari Goyal
Designation: Chief - Medical Oncology (Unit I)
Specialty :
Hematology, Oncology
Location :
Nationality :
Languages Spoken :
Hindi, Punjabi, Telugu
Gender :
Artemis Hospitals


MD (Internal Medicine), SMS Medical College, Jaipur
DM (Oncology), AIIMS, New Delhi
Formerly Junior Registrar, Tata Memorial Centre, Mumbai
Professional Diploma in Clinical Research
Brief Profile

Dr. Hari Goyal had the privilege to work in best of Cancer Centers of India. He started his career in the field of Oncology at Tata Memorial Centre & did the prestigious course of DM from All India Institute of Medical Sciences, New Delhi.

He is the head of Oncology unit comprising eminent doctors like Dr. Deepak Singla, Dr. Mohit Saxena & Dr. Smita B. Choudhury. The team effort gives an edge & advantage to the patients’ management.

His practice has a major influence of teachings of pioneers in oncology, Dr. S.H. Advani, Dr. Vinod Kochupillai & Dr. Lalit Kumar. He has long associations with experts like Dr. P.K. Julka, Dr. Subodh Pandey, Dr. S. Hukku, Dr. Sudhir Bahadur & Dr. K.K. Pandey.

His yesteryear colleagues are now prominent cancer specialists & are heading the cancer department of big institutions across the country and other part of the globe.

His contribution to oncology is immense & has developed drugs for the management of chemotherapy side effects. This development has helped millions of cancer patients since 2004. He was a part of large number of clinical trials of cancer research & has a good number of ongoing studies. He has many prestigious awards to his credit which reflect his dedication, in-depth knowledge & collaboration with other departments to cure cancer.

Immunotherapy in cancer is evolving very rapidly and a large number of patients are getting significant improvements in quality of life. Experience of these drugs in patients as well as in pivotal international clinical trials has made him one of the forerunners in the quest to control disease through immunotherapy. In depth knowledge & intent of these molecules is immense & it directs him to select patients who can be benefited or not from immunotherapy. Presently he is running clinical trial on drugs like : Durvalumab, Tremelimumab, Atezolizumab and others.

Oncology patients from around 25 to 28 countries visit him regularly and he is one of the first choice for people travelling to India for oncology treatment. The list includes patients from Africa, Europe and Asia. Dr. Goyal is a well renowned and distinguished name in these continents. He helps these patients and provides them with crystal clear picture of outcome, treatment and cost. The affection he has and the respect he is getting from these patients is unparalleled.

His communication, truthful discussions about outcome & energetic attitude is the key to his present success. Consistency, punctuality & empathy are some of his qualities which are admired by his patients & colleagues. A hard worker with a positive attitude towards the sick, he deals with all kinds of cancer. He has a passion for cure & control of cancer which make him an exceptional oncologist. His motto is to provide comprehensive & holistic treatment to each & every cancer patient.

An expert of traditional drugs to recent advances, he is a hope, constant support & a friend of cancer patients & their families. He is adored by one & all. He is a versatile personality & a prolific writer. He is an expert of calligraphy & considered as a motivational guru by hundreds.

Honors & Awards:

• Triveni Ratna Award given by Member of Parliament, Shri Mahabal Mishra
• Unnat Bharat Seva given by Union Minister of Agriculture at Parliament Annexe
• Awards at many local functions across the country.

Clinical Focus:

• Holistic approach towards cancer patients.
• Try to give cure, control and care by best possible means.


All procedures related to the specialty.


Over 30 National & international publications.

Recent ongoing trials
1. Clinical research associate in protocol 94CE 32 .Phase III comparative study of combination treatment with TLC D99 liposomal doxorubicin and cyclophosphamide and doxorubicin in metastatic breast cancer.

2. A Multicentric, open label phase III clinical trial to evaluate the safety of filgrastim in cancer patients with grade 3 or 4 chemotherapy induced neutropenia.

3. Organizing secretary, 4th international seminar on psychosocial oncology, new delhi ,april 1999.

4. TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer”.

5. SB3-G31-BC: “A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting”.

6. A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer or Colorectal cancer under fed condition.

7. A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients.

8. A multicenter, open label, balanced, randomized, two treatment, three period, three sequence, reference replicate crossover, single dose, oral bioequivalence study of Capecitabine film coated tablets 500mg of Shilpa Medicare Limited, India & Xeloda film coated tablets 500mg (Capecitabine) marketed by Roche Registration limited, 6 Falcon way, Shire park, Welwyn garden city, AL71 TW United Kingdome following single oral dose of 2000mg (4x500mg) in adult human cancer patients under fed conditions.